Neuropeptides involved in the pathophysiology of schizophrenia and major depression

Neurotoxicity Research

Volumn 4, Issue 5-6, 2002, Pages 453-468

  De Wied, David ^a   Sigling, Hein O ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CRH neurotensin; Major depression; Neuropeptides; Schizophrenia; Vasopressin

Indexed keywords

BETA ENDORPHIN; CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; FLUOXETINE; GAMMA ENDORPHIN; GAMMA ENDORPHIN[DEENKEPHALIN]; GAMMA ENDORPHIN[DETYROSINE]; HALOPERIDOL; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; PAROXETINE; PLACEBO; PROTIRELIN; SOMATOSTATIN; THIORIDAZINE; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID RELEASE; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANIMALIA;

EID: 0036694755     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1080/10298420290031432     Document Type: Review

References (216)

1. Agren, H. and Lundqvist, G. (1984) "Low levels of somatostatin in human CSF mark depressive episodes", Psychoneuroendocrinology 9, 233-248.
2. Albus, M., Von Gellhorn, K., Munch, U., Naber, D. and Ackenheil, M. (1986) "A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results", Psychiatry Res. 19, 1-7.
3. Arato, M., Banki, C.M., Nemeroff, C.B. and Bissette, G. (1986) "Hypothalamic-pituitary-adrenal axis and suicide", Ann. NY Acad. Sci. 487, 263-270.
4. Arato, M., Banki, C.M., Bissette, G. and Nemeroff, C.B. (1989) "Elevated CSF CRIF in suicide victims", Biol. Psychiatry 25, 355-359.
5. Arborelius, L., Owens., M.J., Plotsky, P.M. and Nemeroff, C.B. (1999) "The role of corticotropin-releasing factor in depression and anxiety disorders", J. Endocrinol. 160, 1-12.
6. Asher, R. (1949) "Myxoedematous madness", Br. Med. J. 22, 555-562.
7. Austin, J., Hoogendoorn, B., Buckland, P., Speight, G., Cardno, A., Bowen, T., Williams, N., Spurlock, G., Sanders, R., Jones, L., Murphy, K., McCarthy, G., McGuffin, P., Owen, M.J. and O'Donovan, M.C. (2000a) "Comparative sequencing of the proneurotensin gene and association studies in schizophrenia", Mol. Psychiatry 5(2), 208-212.
8. Austin, J., Buckland, P., Cardno, A.G., Williams, N., Spurlock, G., Hoogendoorn, B., Zammit, S., Jones, G., Sanders, R., Jones, L., McCarthy, G., Jones, S., Bray, N.J., McGuffin, R, Owen, M.J. and O'Donovan, M.C. (2000b) "The high affinity neurotensin receptor gene (NTSR1): comparative sequencing and association studies in schizophrenia", Mol. Psychiatry 5(5), 552-557.
9. Azorin, J.M., Blum, A., Charbaut, J., Escande, M., Granier, F., Huber, J.P., Metzger, J.Y., Richou, H., Sitsen, A., Van Amerongen, P., et al. (1990) "Des-enkephalin-gamma-endorphin in the treatment of schizophrenia", Int. Clin. Psychopharmacol. 5, 205-215.
10. Bachus, S.E., Hyde, T.M., Herman, M.M., Egan, M.F. and Kleinman, J.E. (1997) "Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics", J. Psychiatr. Res. 31, 233-256.
11. Banki, C.M., Bissette, G., Arato, M., O'Connor, L. and Nemeroff, C.B. (1987) "CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia", Am. J. Psychiatry 144, 873-877.
12. Banki, C.M., Bissette, G., Arato, M. and Nemeroff, C.B. (1988) "Elevation of immunoreactive CSF TRH in depressed patients", Am. J. Psychiatry 145, 1526-1531.
13. Banki, C.M., Karmacsi, L., Bissette, G. and Nemeroff, C.B. (1992a) "CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia", Psychiatry Res. 43(1), 13-21.
14. Banki, C.M., Karmacsi, L., Bissette, G. and Nemeroff, C.B. (1992b) "Cerebrospinal fluid neuropeptides in mood disorder and dementia", J. Affect. Disord. 25, 39-45.
15. Barberis, C. and Tribollet, E. (1996) "Vasopressin and oxytocin receptors in the central nervous system", Crit. Rev. Neurobiol. 10, 119-154.
16. Beal, M.F., Svendsen, C.N., Bird, E.D. and Martin, J.B. (1987) "Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia", Neurochem. Pathol. 6(3), 169-176.
17. Bean, A.J., Dagerlind, A., Hokfelt, T. and Dobner, P.R. (1992) "Cloning of human neurotensin/neuromedin N genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls", Neuroscience 50(2), 259-268.
18. Beckmann, H., Lang, R.E. and Gattaz, W.E. (1985) "Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls", Psychoneuroendocrinology 10, 187-191.
19. Beinfeld, M.C. and Garver, D.L. (1991) "Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response", Prog. Neuropsychopharmacol. Biol. Psychiatry 15, 601-609.
20. Berrettini, W.H., Rubinow, D.R., Nurnberger, Jr, J.I., Simmons-Alling, S., Post, R.M. and Gershon, E.S. (1985) "CSF substance P immunoreactivity in affective disorders", Biol. Psychiatry 20, 965-970.
21. Berrettini, W.H., Doran, A.R., Kelsoe, J., Roy, A. and Pickar, D. (1987) "Cerebrospinal fluid neuropeptide Y in depression and schizophrenia", Neuropsychopharmacology 1(1), 81-83.
22. Biggins, J.A., Perry, E.K., McDermott, J.R., Smith, A.I., Perry, R.H. and Edwardson, J.A. (1983) "Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression", J. Neurol. Sci. 58(1), 117-122.
23. Bissette, G., Widerlov, E., Walleus, H., Karlsson, I., Eklund, K., Forsman, A. and Nemeroff, C.B. (1986) "Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders", Arch. Gen. Psychiatry 43, 1148-1151.
24. Bloom, F., Segal, D., Ling, N. and Guillemin, R. (1976) "Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness", Science 194, 630-632.
25. Bourgeois, M., Laforge, E., Muyard, J., Blayac, J. and Lemoine, J. (1980) "Endorphins and schizophrenias. II. Trial treatment of schizophrenia with des-Tyr-gamma-endorphin (DT gamma E) (including a personal trial)", Ann. Med. Psychol. (Paris) 138, 1112-1119.
26. Brambilla, F., Aguglia, E., Massironi, R., Maggioni, M., Grillo, W., Castiglioni, R., Catalano, M. and Drago, F. (1986) "Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration", Neuropsychobiology 15, 114-121.
27. Brambilla, F., Bondiolotti, G.P., Maggioni, M., Sciascia, A., Grillo, W., Sanna, F., Latina, A. and Picotti, G.B. (1989) "Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory", Neuropsychobiology 20, 113-119.
28. Breslin, N.A., Suddath, R.L., Bissette, G., Nemeroff, C.B., Lowrimore, P. and Weinberger, D.R. (1994) "CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates", Schizophr. Res. 12(1), 35-41.
29. Burnet, P.W. and Harrison, P.J. (2000) "Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia", Biol. Psychiatry 47, 80-83.
30. Caberlotto, L. and Hurd, Y.L. (1999) "Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder", Neuroreport 10(8), 1747-1750.
31. Caberlotto, L. and Hurd, Y.L. (2001) "Neuropeptide Y Y(1)and Y(2) receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y(2) subtype to suicidal behavior", Neuropsychopharmacology 25(1), 91-97.
32. Carraway, R.E. and Leeman, S.E. (1973) "The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami", J. Biol. Chem. 248, 6854.
33. Carraway, R.E. and Leeman, S.E. (1976) "Characterization of radioimmunoassayable neurotensin in the rat: its differential distribution in the central nervous system, small intestine and stomach", J. Biol. Chem. 254, 7045.
34. Carroll, B.J. (1982) "Use of the dexamethasone suppression test in depression", J. Clin. Psychiatry 43, 44-50.
35. Casey, D.E., Korsgaard, S., Gerlach, J., Jorgensen, A. and Simmelsgaard, H. (1981) "Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia", Arch. Gen. Psychiatry 38, 158-160.
36. Charlton, B.G., Wright, C., Leake, A., Ferrier, I.N., Cheetham, S.C., Horton, R.W., Crompton, M.R. and Katona, C.L. (1988) "Somatostatin immunoreactivity in postmortem brain from depressed suicides", Arch. Gen. Psychiatry 45, 597-598.
37. Coppen, A. (1967) "The biochemistry of affective disorders", Br. J. Psychiatry 113, 1237-1264.
38. Crawley, J.N. (1991) "Cholecystokinin-dopamine interactions", Trends Pharmacol. Sci. 12, 232-236.
39. Croiset, G., Nijsen, M.J. and Kamphuis, P.J. (2000) "Role of corticotropin-releasing factor, vasopressin and the autonomic nervous system in learning and memory", Eur. J. Pharmacol. 405, 225-234.
40. DeBattista, C., Posener, J.A., Kalehzan, B.M. and Schatzberg, A.F. (2000) "Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study", Am. J. Psychiatry 157, 1334-1337.
41. De Bellis, M.D., Gold, RW, Geracioti, Jr., T.D., Listwak, S.J. and Kling, M.A. (1993) "Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression", Am. J. Psychiatry 150, 656-657.
42. De Souza, E.B. (1995) "Corticotropin-releasing factor receptors: physiology pharmacology, biochemistry and role in central nervous system and immune disorders", Psychoneuroendocrinology 20, 789-819.
43. Detera-Wadleigh, S.D., de Miguel, C., Berrettini, W.H., DeLisi, L.E., Goldin, L.R. and Gershon, E.S. (1987) "Neuropeptide gene polymorphisms in affective disorder and schizophrenia", J. Psychiatr. Res. 21, 581-587.
44. De Wied, D., Kovacs, G.L., Bohus, B., Van Ree, J.M. and Greven, H.M. (1978) "Neuroleptic activity of the neuropeptide beta-LPH62-77 ([Des-Tyr1]gamma-endorphin; DT gamma E)", Eur. J. Pharmacol. 49, 427-436.
45. De Wied, D. and Burbach, J.P.H. (1999) "Neuropeptides and behavior", In: Adelman, G. and Smith, B.H., eds, Encyclopedia of Neuroscience (Birkhäuser, Boston), pp 1431-1436.
46. Dinan, T.-G. (1994) "Glucocorticoids and the genesis of depressive illness. A psychobiological model", Br. J. Psychiatry 164, 365-371.
47. Dinan, T.G., Lavelle, E., Scott, L.V., Newell-Price, J., Medbak, S. and Grossman, A.B. (1999) "Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity", J. Clin. Endocrinol. Metab. 84, 2238-2240.
48. Doran, A.R., Rubinow, D.R., Roy, A. and Pickar, D. (1986) "CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients", Arch. Gen. Psychiatry 43, 365-369.
49. Duval, F., Macher, J.P. and Mokrani, M.C. (1990) "Difference between evening and morning thyrotropin responses to protirelin in major depressive episode", Arch. Gen. Psychiatry 47, 443-448.
50. Duval, F., Mokrani, M.C., Bailey, R., Correa, H., Diep, T.S., Crocq, M.A. and Macher, J.P. (1999) "Thyroid axis activity and serotonin function in major depressive episode", Psychoneuroendocrinology 24, 695-712.
51. Emrich, H.M., Zaudig, M., Kissling, W., Dirlich, G., von Zerssen, D. and Herz, A. (1980) "Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients", Pharmakopsychiatr. Neuro-Psychopharmakol. 13, 290-298.
52. Farmery S.M., Owen, F., Poulter, M. and Crow, T.J. (1985) "Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients", Life Sci. 36, 473-477.
53. Ferrier, I.N., Roberts, G.W., Crow, T.J., Johnstone, E.C., Owens, D.G., Lee, Y.C., O'Shaughnessy, D., Adrian, T.E., Polak, J.M. and Bloom, S.R. (1983) "Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia", Life Sci, 33, 475-482.
54. Fink, M., Papakostas, Y. and Lee, J. (1981) "Clinical trials with des-tyr-gamma-endorphin (GK-78)", In: Perris, C., Strome, G. and Jansson, B., eds, Biological Psychiatry (Elsevier/North-Holland Biomedical Press, Amsterdam).
55. France, R.D., Urban, B., Krishnan, K.R., Bissett, G., Banki, C.M., Nemeroff, C. and Speilman, F.J. (1988) "CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression", Biol. Psychiatry 23, 86-88.
56. Frasch, A., Zetzsche, T., Steiger, A. and Jirikowski, G.F. (1995) "Reduction of plasma oxytocin levels in patients suffering from major depression", Adv. Exp. Med. Biol. 395, 257-258.
57. Frederiksen, S.O., Ekman, R., Gottfries, C.G., Widerlov, E. and Jonsson, S. (1991) "Reduced concentrations of galanin, arginine vasopressin, neuropepticle Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics", Acta Psychiatr. Scand. 83, 273-277.
58. Frye, M.A., Dunn, R.T., Gary, K.A., Kimbrell, T.A., Callahan, A.M., Luckenbaugh, D.A., Cora-Locatelli, G., Vanderham, E., Winokur, A. and Post, R.M. (1999) "Lack of correlation between cerebrospinal fluid thyrotropin-releasing hormone (TRH) and TRH-stimulated thyroid-stimulating hormone in patients with depression", Biol. Psychiatry 45, 1049-1052.
59. Gabriel, S.M., Davidson, M., Haroutunian, V., Powchik, P., Bierer, L.M., Purohit, D.R, Perl, D.P. and Davis, K.L. (1996) "Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex", Biol. Psychiatry 39, 82-91.
60. Gaffori, O., Stewart, J.M. and De Wied, D. (1984) "Influence of substance P and fragments on passive avoidance behavior", Experientia 40, 89-91.
61. Garver, D.L., Beinfeld, M.C. and Yao, J.K. (1990) "Cholecystokinin, dopamine and schizophrenia", Psychopharmacol. Bull. 26, 377-380.
62. Garver, D.L., Bissette, G., Yao, J.K. and Nemeroff, C.B. (1991) "Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients", Am. J. Psychiatry 148(4), 484-488.
63. Geracioti, Jr, T.D., Orth, D-N., Ekhator, N.N., Blumenkopf, B. and Loosen, P.T. (1992) "Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans", J. Clin. Endocrinol. Metab. 74, 1325-1330.
64. Gerner, R.H. and Yamada, T. (1982) "Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients", Brain Res. 238, 298-302.
65. Gerner, R.H., van Kammen, D.P. and Ninan, P.T. (1985) "Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals", Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 73-82.
66. Gispen-de Wied, C.C., Kok, F.W., Koppeschaar, H.P., Wynne, H.J., Westenberg, H.G., Thijssen, J.H. and Van Ree, J.M. (1993) "Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study", Eur. Neuropsychopharmacol. 3, 533-541.
67. Gjerris, A., Hammer, M., Vendsborg P., Christensen, N.J. and Rafaelsen, O.J. (1985) "Cerebrospinal fluid vasopressin - changes in depression", Br. J. Psychiatry 147, 696-701.
68. Gjerris, A., Widerlov, E., Werdelin, L. and Ekman, R. (1992) "Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls", J. Psychiatry Neurosci. 17(1), 23-27.
69. Glovinsky, D., Kalogeras, K.T., Kirch, D.G., Suddath, R. and Wyatt, R.J. (1994) "Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication", Schizophr. Res. 11, 273-276.
70. Gold, P.W., Goodwin, F.K., Post, R.M. and Robertson, G.L. (1981) "Vasopressin function in depression and mania [proceedings]", Psychopharmacol. Bull. 17, 7-9.
71. Goldstein, G., Fava, M., Culler, M., Fisher, A., Rickels, K., Lydiard, R.B. and Rosenbaum, J. (2000) "Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression", Biol. Psychiatry 48, 65-69.
72. Harrison, S. and Geppetti, P. (2001) "Substance P", Int. J. Biochem. Cell Biol. 33, 555-576.
73. Hashimoto, H., Onishi, H., Koide, S., Kai, T. and Yamagami, S. (1996) "Plasma neuropeptide Y in patients with major depressive disorder", Neurosci. Lett. 216(1), 57-60.
74. Heikkila, L. (1993) "Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment", Schizophr. Res. 8(3), 273-277.
75. Heikkila, L., Rimon, R., Terenius, L. and Dynorphin, A. (1990) "substance P in the cerebrospinal fluid of schizophrenic patients", Psychiatry Res. 34, 229-236.
76. Hein, M.D. and Jackson, I.M. (1990) "Review: thyroid function in psychiatric illness", Gen. Hosp. Psychiatry 12, 232-244.
77. Hermes, M.L. and Renaud, L.P. (1993) "Differential responses of identified rat hypothalamic paraventricular neurons to suprachiasmatic nucleus stimulation", Neuroscience 56, 823-832.
78. Heuser, I., Bissette, G., Dettling, M., Schweiger, U., Gotthardt, U., Schmider, J., Lammers, C.H., Nemeroff, C.B. and Holsboer, F. (1998) "Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment", Depress. Anxiety 8, 71-79.
79. Holsboer, F. (2000) "The corticosteroid receptor hypothesis of depression", Neuropsychopharmacology 23, 477-501.
80. Holsboer, F. and Barden, N. (1996) "Antidepressants and hypothalamic-pituitary-adrenocorticaI regulation", Endocr. Rev. 17, 187-205.
81. Holsboer, F., Lauer, C.J., Schreiber, W. and Krieg, J.C. (1995) "Altered hypothalamic-pituitary-adrenocorticaI regulation in healthy subjects at high familial risk for affective disorders", Neuroendocrinology 62, 340-347.
82. Hommer, D.W., Pickar, D., Roy, A., Ninan, P., Boronow, J. and Paul, S.M. (1984) "The effects of ceruletide in schizophrenia", Arch. Gen. Psychiatry 41, 617-619.
83. Hoogendijk, W.J., Purba, J.S., Holman, M.A., de Vos, R.A., Jansen, E.N. and Swaab, D.F. (1998) "Depression in Parkinson's disease is not accompanied by more corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus", Biol. Psychiatry 43, 913-917.
84. Hucks, D., Lowther, S., Crompton, M.R., Katona, C.L. and Horton, R.W. (1997) "Corticotropin-releasing factor binding sites in cortex of depressed suicides", Psychopharmacology (Berl) 134, 174-178.
85. Iadarola, M.J., Ofri, D. and Kleinman, J.E. (1991) "Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients", Life Sci. 48, 1919-1930.
86. Iager, A.C., Kirch, D.G., Bigelow, L.B. and Karson, C.N. (1986) "Treatment of schizophrenia with a vasopressin analogue", Am. J. Psychiatry 143, 375-377.
87. Inder, W.J., Donald, R.A., Prickett, T.C., Frampton, C.M., Sullivan, P.F., Mulder, R.T. and Joyce, R.R. (1997) "Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression", Biol. Psychiatry 42, 744-747.
88. Iritani, S., Kuroki, N., Niizato, K. and Ikeda, K. (2000) "Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizcophrenics", Prog. Neuropsychopharmacol. Biol. Psychiatry 24(2), 241-249.
89. Irwin, M., Brown, M., Patterson, T., Hauger R., Mascovich, A. and Grant, I. (1991) "Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress", FASEB. J. 5(15), 3100-3107.
90. Ishunina, T.A. and Swaab, D.F. (1999) "Vasopressin and oxytocin neurons of the human supraoptic and paraventricular nucleus: size changes in relation to age and sex", J. Clin. Endocrinol. Metab 84, 4637-4644.
91. Jackson I.M. (1998) "The thyroid axis and depression", Thyroid 8, 951-956.
92. Jacquet, Y.F. and Marks, N. (1976) "The C-fragment of beta-lipotropin: an endogenous; neuroleptic or antipsychotogen?", Science 194, 632-635.
93. Joja, O., Goldstein, R. and Popa, M. (1993) "Vasotocin effects in depressive patients with eating disorders", Rom. J. Endocrinol. 31, 171-177.
94. Kaiya, H., Tamura, Y., Adachi, S., Moriuchi, I., Namba, M., Tanaka, M., Yoshida, H., Yanaihara, N. and Yanaihara, C. (1981) "Substance P-like immunoreactivity in plasma of psychotic patients and effects of neuroleptics and electroconvulsive therapy", Psychiatry Res. 5, 11-21.
95. Kasckow, J.W., Baker, D. and Geracioti, Jr., T.D. (2001) "Corticotropin-releasing hormone in depression and post-traumatic stress disorder", Peptides 22, 845-851.
96. Kathol, R.G., Jaeckle, R.S., Lopez, J.-F. and Meller, W.H. (1989) "Consistent reduction of ACTH responses to stimulation with CRH, vasopressin and hypoglycaemia in patients with major depression", Br. J. Psychiatry 155, 468-478.
97. Keck, M.E. and Holsboer, F. (2001) "Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders", Peptides 22, 835-844.
98. Kerwin, R., Robinson, P. and Stewart, J.M. (1992) "Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study", Psychol. Med. 22, 37-43.
99. Kirkegaard, C., Faber, J., Hummer, L. and Rogowski, P. (1979) "Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression", Psychoneuroendocrinology 4, 227-235.
100. Kinkead, B. and Nemeroff, C.B. (2002) "Neurotensin: an endogenous antipsychotic?", Curr. Opin. Pharmacol. 2(1), 99-103.
101. Kissling, W., Moller, J.H., Cootjans, J., Roy, D., Husebö, B., Christiansen, P. and Godt, H.H. (1986). "Multicenter double-blind comparison between des-enkephalin-γ-endorphin (DEγE, Org 5878) and haloperidol concerning the efficacy and safety in the treatment of schizophrenia". In: Psychiatry, Its Related Disciplines, the Next 25 Years: World Psychiatric Association, Regional Symposium, p. 178.
102. Kleinman, J.E., Hong, J., Iadarola, M., Govoni, S. and Gillin, C.J. (1985) "Neuropeptides in human brain-postmortem studies", Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 91-95.
103. Kling, M.A., Roy, A., Doran, A.R., Calabrese, J.R., Rubinow, D.R., Whitfield, Jr, H.J., May, C., Post, R.M., Chrousos, G.P. and Gold, P.W. (1991) "Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications", J. Clin. Endocrinol. Metab. 72, 260-271.
104. Kling, M.A., Rubinow, D.R., Doran, A.R., Roy, A., Davis, C.L., Calabrese, J.R., Nieman, L.K., Post, R.M., Chrousos, G.P. and Gold, P.W. (1993) "Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretion", Neuroendocrinology 57, 79-88.
105. Korsgaard, S., Casey, D.E., Damgaard Pedersen, N.E., Jorgensen, A. and Gerlach, J. (1981) "Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo", Psychopharmacology (Berl) 74, 379-382.
106. Korsgaard, S., Casey, D.E. and Gerlach, J. (1982) "High-dose destyrosine-gamma-enclorphin in tardive dyskinesia", Psychopharmacology (Berl) 78, 285-286.
107. Kramer, M.S. (2000) "Update on substance P (NK-1 receotir) antagonists in clinical trials for depression", Neuropeptides 34, 255.
108. Kramer, M.S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J.J., Reines, S.A., Liu, G., Snavely, D., Wyatt-Knowles, E., Hale, J.J., Mills, S.G., MacCoss, M., Swain, C.J., Harrison, T., Hill, R.G., Hefti, F., Scolnick, E.M., Cascieri, M.A., Chicchi, G.G., Sadowski, S., Williams, A.R., Hewson, L., Smith, D., Rupniak, N.M., et al. (1998) "Distinct mechanism for antidepressant activity by blockade of central substance P receptors", Science 281, 1640-1645.
109. Lahti, R.A., Cochrane, E.V., Roberts, R.C., Conley, R.R. and Tamminga, C.A. (1998) "[3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study", J. Neural Transm. 105(4-5), 507-516.
110. Laruelle, M., Seghers, A., Goffinet, S., Bouchez, S. and Legros, J.J. (1990) "Plasmatic vasopressin neurophysin in depression: basic levels and relations with HPA axis", Biol. Psychiatry 27, 1249-1263.
111. Leake, A., Perry, E.K., Perry, R.H., Fairbairn, A.F. and Ferrier, I.N. (1990) "Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression", Biol. Psychiatry 28, 603-608.
112. Legros, J.J. and Louis, F. (1973) "Identification of a vasopressin-neurophysin and of an oxytocin-neurophysin in man", Neuroendocrinology 13, 371-375.
113. Legros, JJ., Gazzotti, C., Carvelli, T., Franchimont, P., Timsit-Berthier, M., von Frenckell, R. and Ansseau, M. (1992) "Apomorphine stimulation of vasopressin- and oxytocin- neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics", Psychoneuroendocrinology 17, 611-617.
114. Leibowitz, S.F. (1994) "Specificity of hypothalamic peptides in the control of behavioral and physiological processes", Ann. NY Acad. Sci. 739, 12-35.
115. Lembeck, F. (1953) "Zur Frage der zentralen Übertragung afferenter Impulse. III. Mittelung. Den Vorkommen und die Bedeutung der Substanz P in den dorsalen Wurzeln des Rückenmarks", Arch. Exp. Pathol. Pharmakol. 219, 197-213.
116. Lenzinger, E., Meszaros, K., Hornik, K., Parzer, P., Hollerer, E., Langer, G., Resch, F. and Legros, J.J. (1996) "Correlation between vasopressin baseline and TSH-blunting in depressives", Biol. Psychiatry 39, 341-345.
117. Lesch, K.P., Laux, G., Pfuller, H., Erb, A. and Beckmann, H. (1987) "Growth hormone (GH) response to GH-releasing hormone in depression", J. Clin. Endocrinol. Metab. 65, 1278-1281.
118. Lesch, K.P., Widerlov, E., Ekman, R., Laux, G., Rupprecht, R., Schulte, H.M. and Beckmann, H. (1989) "The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls", J. Neural Transm. 75, 111-118.
119. Lindstrom, L.H., Widerlov, E., Bisette, G. and Nemeroff, C. (1988) "Reduced CSF neurotensin concentration in drug-free schizophrenic patients", Schizophr. Res. 1(1), 55-59.
120. Linkowski, P., Geenen, V., Kerkhofs, M., Mendlewicz, J. and Legros, J.J. (1984) "Cerebrospinal fluid neurophysins in affective illness and in schizophrenia", Eur. Arch. Psychiatry Neurol. Sci. 234, 162-165.
121. Liu, R.Y., Zhou, J.N., Hoogendijk, W.J., van Heerikhuize, J., Kamphorst, W., Unmehopa, U.A., Hofman, M.A. and Swaab, D.F. (2000) "Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression", J. Neuropathol. Exp. Neurol. 59, 314-322.
122. Lolait, S.J., O'Carroll, A.M., Mahan, L.C., Felder, C.C., Button, D.C., Young III, W.S., Mezey, E. and Brownstein, M.J. (1995) "Extrapituitary expression of the rat V1b vasopressin receptor gene", Proc. Natl Acad. Sci. USA 92, 6783-6787.
123. Lotstra, F., Verbanck, P., Mendlewicz, J. and Vanderhaeghen, J.J. (1984) "No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics; a double-blind cross-over study", Biol. Psychiatry 19, 877-882.
124. Mai J.K., Berger, K., and Sofroniew, M.V. (1993) "Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia", J. Hirnforsch. 34, 133-154.
125. Manchanda, R. and Hirsch, S.R. (1981) "(Des-Tyr)-gamma-endorphin in the treatment of schizophrenia", Psychol. Med. 11, 401-404.
126. Mattes, J.A., Hom, W. and Rochford, J.M. (1985a) "A high-dose, double-blind study of ceruletide in the treatment of schizophrenia", Am. J. Psychiatry 142, 1482-1484.
127. Mattes, J.A., Hom, W., Rochford, J.M. and Orlosky, M. (1985b) "Ceruletide for schizophrenia: a double-blind study", Biol. Psychiatry 20, 533-538.
128. Mauri, M.C., Rudelli, R., Vanni, S., Panza, G., Sicaro, A., Audisio, D., Sacerdote, P. and Panerai, A.E. (1998) "Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls" Psychiatry Res. 78, 45-50.
129. McMahon, B.M., Boules, M., Warrington, L. and Richelson, E. (2002) "Neurotensin analogs indications for use as potential antipsychotic compounds", Life Sci. 70(10), 1101-1119.
130. Meltzer, H.Y., Busch, D.A., Tricou, B.J. and Robertson, A. (1982) "Effect of (Des-Tyr)-gamma-endorphin in schizophrenia", Psychiatry Res. 6, 313-326.
131. Miller, C., Kirchmair, R., Troger, J., Saria, A., Fleischhacker, W.W., Fischer-Colbrie, R., Benzer, A. and Winkler, H. (1996) "CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin)", Biol. Psychiatry 39, 911-918.
132. Mizuki, Y., Ushijima, I., Yamada, M., Tanaka, M. and Inanaga, K. (1986) "A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin in schizophrenia", Int. Clin. Psychopharmacol. 1, 303-313.
133. Modell, S., Lauer, C.J., Schreiber, W., Huber, J., Krieg, J.C. and Holsboer, F. (1998) "Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders", Neuropsychopharmacology 18, 253-262.
134. Molchan, S.E., Lawlor, B.A., Hill, J.L., Martinez, R.A., Davis, C.L., Mellow, A.M., Rubinow, D.R. and Sunderland, T. (1991) "CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression", Biol. Psychiatry 29, 1110-1118.
135. Molchan, S.E., Hill, J.L., Martinez, R.A., Lawlor, B.A., Mellow, A.M., Rubinow, D.R., Bissette, G., Nemeroff, C.B. and Sunderland, T. (1993) "CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures", Psychoneuroendocrinology 18, 509-519.
136. Montgomery, S.A., Green, M., Rimon, R., Heikkila, L., Forsstrom, R., Hirsch, S.R., Hallstrom, C., Hippius, H., Naber, R., Khan, M.C., et al. (1992) "Inadequate treatment response to des-enkephalin-gamma-endorphin compared with thioridazine and placebo in schizophrenia", Acta Psychiatr. Scand. 86, 97-103.
137. Nair, N.P., Bloom, D.M., Debonnel, G., Schwartz, G. and Mosticyan, S. (1984) "Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study", Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 711-714.
138. Nakase, S., Kitayama, L., Soya, H., Hamanaka, K. and Nomura, J. (1998) "Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats", Life Sci. 63, 23-31.
139. Nemeroff, C.B. (1980) "Neurotensin: perchance an endogenous neuroleptic?", Biol. Psychiatry 15(2), 283-302.
140. Nemeroff, C.B., Youngblood, W.W., Manberg, P.J., Prange, Jr., A.J. and Kizer, J.S. (1983) "Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia", Science 221(4614), 972-975.
141. Nemeroff, C.B., Witlerlov, E., Bissette, G., Walleus, H., Karlsson, L., Eklund, K., Kilts, C.D., Loosen, P.T. and Vale, W. (1984) "Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients", Science 226, 1342-1344.
142. Nemeroff, C.B., Owens, M.J., Bissette, G., Andorn, A.C. and Stanley, M. (1988) "Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims", Arch. Gen. Psychiatry 45, 577-579.
143. Nemeroff, C.B., Bissette, G., Widerlov, E., Beckmann, H., Gerner, R., Manberg, P.J., Lindstrom, L., Prange, Jr., A.J. and Gattaz, W.F. (1989) "Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome", J. Neuropsychiatry Clin. Neurosci. 1(1), 16-20.
144. Nilsson, C., Karlsson, G., Blennow, K., Heilig, M. and Ekman, R. (1996) "Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients", Peptides. 17(3), 359-362.
145. Ordway, G.A., Stockmeier, C.A., Meltzer, H.Y., Overholser, J.C., Jaconetta, S. and Widdowson, P.S. (1995) "Neuropeptide Y in frontal cortex is not altered in major depression", J. Neurochem. 65(4), 1646-1650.
146. Palacios, J.M., Rigo, M., Chinaglia, G. and Probst, A. (1990) "Reduced density of striatal somatostatin receptors in Huntington's chorea", Brain Res. 522(2), 342-346.
147. Palacios, J.M., Chinaglia, G., Rigo, M., Ulrich, J. and Probst, A. (1991) "Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia", Synapse 7(2), 114-122.
148. Panza, G., Monzani, E., Sacerdote, P., Penati, G. and Panerai, A.E.
149. Peselow, E., Angrust, B., Sudilovsky, A., Corwin, J., Siekierski, J., Trent, F. and Rotrosen, J. (1987) "Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia", Psychopharmacology (Berl). 91, 80-84.
150. Peters, J., Van Kammen, D.P., Gelernter, J., Yao, J. and Shaw, D. (1990) "Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures", Schizophr. Res. 3(5,6), 287-294.
151. Pitts, A.F., Samuelson, S.D., Meller, W.H., Bissette, G., Nemeroff, C.B. and Kathol, R.G. (1995) "Cerebrospinal fluid corticotropin-releasing hormone, vasopressin and oxytocin concentrations in treated patients with major depression and controls", Biol. Psychiatry 38, 330-335.
152. Prange, Jr., A.J., Wilson, I.C., Breese, G.R. and Lipton, M.A. (1975) "Behavioral effects of hypothalamic releasing hormones in animals and men", Prog. Brain Res. 42, 1-9.
153. Price, L.H., Cappiello, A., Malison, R.T., McDougle, C.J., Pelton, G.H., Schollnhammer, G. and Heninger, G.R. (1997) "Effects of antiglucocorticoid treatment on 5-HT1A function in depressed patients and healthy subjects", Neuropsychopharmacology 17, 246-257.
154. Purba, J.S., Hoogendijk, W.J., Hofman, M.A. and Swaab, D.F. (1996) "Increased number of vasopressin- and oxytocin- expressing neurons in the paraventricular nucleus of the hypothalamus in depression", Arch. Gen. Psychiatry 53, 137-143.
155. Raadsheer, F.C., Hoogendijk, W.J., Stain, F.C., Tilders, F.J. and Swaab, D.F. (1994) "Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients", Neuroendocrinology 60, 436-444.
156. Raadsheer, F.C., van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J. and Swaab, D.E. (1995) "Corficotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression", Am. J. Psychiatry 152, 1372-1376.
157. Rafaelsen, O.J. and Gjerris, A. (1985) "Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders", Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 533-538.
158. Raskind, M., Orenstein, H. and Weitzman, R.E. (1979) "Vasopressin in depression", Lancet 1, 164.
159. Reinikainen, K.J., Koponen, H., Jolkkonen, J. and Riekkinen, P.J. (1990) "Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment", Psychiatry Res. 33(3), 307-312.
160. Rimon, R., Le Greves, P., Nyberg, F., Heikkila, L., Salmela, L. and Terenius, L. (1984) "Elevation of substance P-like peptides in the CSF of psychiatric patients", Biol. Psychiatry 19, 509-516.
161. 125I] BH-substance P in schizophrenia", Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 1295-1299.
162. Risch S.C., Lewine, R.J., Jewart, R.D., Pollard, W.E., Caudle, J.M., Kalin, N.H., Stipetic,M., Eccard, M.B. and Risby, E.D. (1991) "Relationship between cerebrospinal fluid peptides and neurotransmitters in depression", In: Risch, S.C., ed, Central Nervous System Peptide Mechanisms in Stress and Depression (American Psychiatric Press, Washington DC).
163. Roberts, G.W., Ferrier, I.N., Lee, Y., Crow, T.J., Johnstone, E.C., Owens, D.G., Bacarese-Hamilton, A.J., McGregor, G., O'Shaughnessey, D. and Polak, J.M. (1983) "Peptides, the limbic lobe and schizophrenia", Brain Res. 288, 199-211.
164. Ronken, E., Wiegant, V.M., Kaspersen, F.M., van Nispen, J.W., de Boer, T., Bruning H.W., Rust, C.J. and Tonnaer, J.A. (1993) "Topography and characteristics of specific binding sites for non-opioid gamma-type endorphins in the rat brain as studied by autoradiography with [35S]Met-desenkephahn-gamma-endorphin", Brain Res. 615, 63-70.
165. Roy, A., Pickar, D., Paul, S., Doran, A., Chrousos, G.P, and Gold, P.W. (1987) "CSF corticotropin-releasing hormone in depressed patients and normal control subjects", Am. J. Psychiatry 144, 641-645.
166. Roy, B.F., Benkelfat, C., Hill, J.L., Pierce, P.F., Dauphin, M.M., Kelly, T.M., Sunderland, T., Weinberger, D.R. and Breslin, N. (1994a) "Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection", Biol. Psychiatry 35(5), 335-344.
167. Roy, A., Wolkowitz, O.M., Bissette, G. and Nemeroff, C.B. (1994b) "Differences in CSF concentrations of thyrotropin-releasing hormone in depressed patients and normal subjects: negative findings", Am. J. Psychiatry 151, 600-602.
168. Rubinow, D.R., Gold, P.W., Post, R.M., Ballenger, J.C., Cowdry, R., Bollinger, J. and Reichlin, S. (1983) "CSF somatostatin in affective illness", Arch. Gen. Psychiatry 40, 409-412.
169. Rupniak, N.M. and Kramer, M.S. (1999) "Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists", Trends Pharmacol. Sci. 20, 485-490.
170. Saiz-Ruiz, J., Carrasco, J.L., Martin, M., Manzanares, J. and Hernanz, A. (1992) "Plasmatic somatostatin as a marker of positive symptoms of schizophrenia", Prog. Neuropsychopharmacol. Biol. Psychiatry 16(2), 203-210.
171. Santarelli, L., Gobbi, G., Debs, P.C., Sibille, E.T., Blier, P., Hen, R. and Heath, M.J. (2001) "Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function", Proc. Natl Acad. Sci. USA 98, 1912-1917.
172. Sattin, A. (1998) "A heuristic model of mental depression derived from basic and applied research on thyrotropin-releasing hormone", Thyroid 8, 957-962.
173. Sawchenko, P.E., Imaki, T., Potter, E., Kovacs, K., Imaki, J. and Vale, W. (1993) "The functional neuroanatomy of corticotropin-releasing factor", Ciba Found. Symp. 172, 5-21.
174. Scott, L.V. and Dinan, T.G. (1998) "Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression", Life Sci. 62, 1985-1998.
175. Sharma, R.P., Janicak, P.G., Bissette, G. and Nemeroff, C.B. (1997) "CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder", Am. J. Psychiatry 154(7), 1019-1021.
176. Siuciak, JA., Lewis, D.R., Wiegand, S.J. and Lindsay, R.M. (1997) "Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)", Pharmacol. Biochem. Behav. 56, 131-137.
177. Sorensen, P.S., Gjerris, A. and Hammer, M. (1985) "Cerebrospinal fluid vasopressin in neurological and psychiatric disorders", J. Neurol. Neurosurg. Psychiatry 48, 50-57.
178. Staner, L., Duval, E., Calvi-Gries, F., Mokrani, M.C., Bailey, P., Hode, Y., Toussaint, M., Luthringer, R., Muzet, A. and Macher, J.P. (2001) "Morning and evening TSH response to TRH and sleep EEG disturbances in major depressive disorder", Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 535-547.
179. Steckler, T., Holsboer, F. and Reul, J.M. (1999) "Glucocorticoids and depression", Bailliere's Best. Pract. Res. Clin. Endocrinol. Metab. 13, 597-614.
180. Tamminga, C.A., Tighe, P.J., Chase, T.N., DeFraites, E.G. and Schaffer, M.H. (1981) "Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report", Arch. Gen. Psychiatry 38, 167-168.
181. Tamminga, C.A., Littman, R.L., Alphs, L.D., Chase, T.N., Thaker, G.K. and Wagman, A.M. (1986) "Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies", Psychopharmacology (Berl) 88, 387-391.
182. Tang, Q., Gandhoke, R., Burritt, A., Hruby, V.J., Porreca, F. and Lai, J. (1999) "High-affinity interaction of (des-Tyrosyl)dynorphin A(2-17) with NMDA receptors", J. Pharmacol. Exp. Ther. 291, 760-765.
183. Tooney, P.A., Crawter, V.C. and Chahl, L.A. (2001) "Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia", Biol. Psychiatry 49, 523-527.
184. Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio H., Ichikawa, H., Kurumaji, A., Takashima, M. and Mataga, N. (1988) "Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients", Acta Psychiatr. Scand. 78, 121-137.
185. Traskman-Bendz, L., Ekman, R., Regnell, G. and Ohman, R. (1992) "HPA-related CSF neuropeptides in suicide attempters", Eur. Neuropsychopharmacol. 2, 99-106.
186. Van Kammen, D.P., Waters, R.N., Gold, P., et al. (1981) "Spinal fluid vasopressin, angiotensin I and II, beta-endorphin and opioid activity in schizophrenia: a preliminary evaluation", In: Perris, C., Struwe, G. and Jansson, B., eds, Biological Psychiatry (Elsevier/North-Holland Biomedical Press, Amsterdam).
187. Van Londen, L., Goekoop, J.G., van Kempen, G.M., Frankhuijzen-Sierevogel, A.C., Wiegant, V.M., van der Velde, E.A. and De Wied, D. (1997) "Plasma levels of arginine vasopressin elevated in patients with major depression", Neuropsychopharmacology 17, 284-292.
188. Van Londen, L., Kerkhof, G.A., Van den, B.F., Goekoop, J.G., Zwinderman, K.H., Frankhuijzen-Sierevogel, A.C., Wiegant, V.M. and De Wied, D. (1998) "Plasma arginine vasopressin and motor activity in major depression", Biol. Psychiatry 43, 196-204.
189. Van Londen, L., Goekoop, J.G., Kerkhof, G.A., Zwinderman, K.H., Wiegant, V.M. and De Wied, D. (2001) "Weak 24-h periodicity of body temperature and increased plasma vasopressin in melancholic depression", Eur. Neuropsychopharmacol. 11, 7-14.
190. Verbanck, P.M., Lotstra, F., Gilles, C., Linkowski, P., Mendlewicz, J. and Vanderhaeghen, J.J. (1984) "Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders", Life Sci. 34, 67-72.
191. Verhoeven, W.M., van Praag, H.M., van Ree, J.M. and de Wied, D. (1979) "Improvement of schizophrenic patients treated with [des-Tyr1]-gamma-endorphin (DTgammaE)", Arch. Gen. Psychiatry 36, 294-298.
192. Verhoeven, W.M., van Ree, J.M., de Wiled, D. and van Praag, H.M. (1981) "Gamma-Type endorphins; and schizophrenia", Arch. Gen. Psychiatry 38, 1182-1183.
193. Verhoeven, W.M., Westenberg, H.G. and Van Ree, J.M. (1986) "A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients", Acta Psychiatr. Scand. 73, 372-382.
194. Verhoeven, W.M., van Ree, J.M., Westenberg, H.G., Krul, J.M., Brouwer, G.J., Thijssen, J.H., de Wied, D., van Praag, H.M., Ceulemans, D.L., Kahn, R.S. (1984) "Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia", Psychiatry Res. 11, 329-346.
195. Virgo, L., Humphries, C., Mortimer, A., Barnes, T., Hirsch, S. and de Belleroche, J. (1995) "Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia", Biol. Psychiatry 37, 694-701.
196. Volavka, J., Hui, K.S., Anderson, B., Nemes, Z., ODonnell, J. and Lajtha, A. (1983) "Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia", Psychiatry Res. 10, 243-252.
197. Von Bardeleben, U. and Holsboer, F. (1989) "Cortisol response to a combined dexamethason-hCRH challenge in patients with depression", J. Neuroendocrinol. 1, 485-488.
198. Von Bardeleben, U., Holsboer, F., Stalla, G.K. and Muller, O.A. (1985) "Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects", Life Sci. 37, 1613-1618.
199. Wei, J., and Hemmings, G.P. (1999) "The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia", Eur. Psychiatry 14, 67-70.
200. Westrin, A., Ekman, R. and Traskman-Bendz, L. (1999) "Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt", Eur. Neuropsychopharmacol. 9(3), 205-211.
201. Westrin, A., Ekman, R., Regnell, G. and Traskman-Bendz, L. (2001) "A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH", Eur. Neuropsychopharmacol. 11, 135-143.
202. Widdowson, P.S., Ordway, G.A. and Halaris, A.E. (1992) "Reduced neuropeptide Y concentrations in suicide brain", J. Neurochem. 59, 73-80.
203. Widerlov, E., Lindstrom, L.H., Besev, G., Manberg, P.J., Nemeroff, C.B., Breese, G.R., Kizer, J.S. and Prange, Jr., A.J. (1982) "Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment", Am. J. Psychiatry 139(9), 1122-1126.
204. Widerlov, E., Lindstrom, L.H., Wahlestedt, C. and Ekman, R. (1988a) "Neuropeptide Y peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively", J. Psychiatr. Res. 22(1), 69-79.
205. Widerlov, E., Bissette, G. and Nemeroff, C.B. (1988b) "Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients", J. Affect. Disord. 14, 99-107.
206. Wiegant, V.M., Ronken, E., Kovacs, G. and De Wied, D. (1992) "Endorphins and schizophrenia", Prog. Brain Res. 93, 433-453.
207. Wolf, S.S., Hyde, T.M., Saunders, R.C., Herman, M.M., Weinberger, D.R. and Kleinman, J.E. (1995) "Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects", J. Neural. Transm. Gen. Sect. 102(1), 55-65.
208. Wolkowitz, O.M. and Reus, V.I. (1999) "Treatment of depression with antiglucocorticoid drugs", Psychosom. Med. 61, 698-711.
209. Wong, M.L., Kling, M.A., Munson, P.J., Listwak, S., Licinio, J., Prolo, P., Karp, B., McCutcheon, I.E., Geracioti, Jr., T.D,, DeBellis, M.D., Rice, K.C., Goldstein, D.S., Veldhuis, J.D., Chrousos, G.P., Oldfield, E.H., McCann, S.M. and Gold, P.W. (2000) "Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone", Proc. Natl Acad. Sci. USA 97, 325-330.
210. Yamamura, Y., Ogawa, H., Chihara, T., Kondo, K., Onogawa, T., Nakamura, S., Mori, T., Tominaga, M. and Yabuuchi, Y. (1991) "OPC-21268, an orally effective, nonpeptide vasopressin VI receptor antagonist", Science 252, 572-574.
211. Zachrisson, O., de Belleroche, J., Wendt, K.R., Hirsch, S. and Lindefors, N. (1999) "Cholecystokinin CCK(B) receptor mRNA isoforms: expression in schizophrenic brains", Neuroreport 10, 3265-3268.
212. Zech, M. and Bogerts, B. (1985) "Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients and schizophrenics. A qualitative immunohistochemical study", Acta Neuropathol. (Berl) 68, 32-38.
213. Zech, M., Roberts, G.W., Bogerts, B., Crow, T.J. and Polak, J.M. (1986) "Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immnohistochemical study", Acta Neuropathol. (Berl) 71(3-4), 259-266.
214. Zhou, J.N., Riemersma, R.F., Unmehopa, U.A., Hoogendijk, W.J., van Heerikhuize, J.J., Hofman, M.A. and Swaab, D.F. (2001) "Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression", Arch. Gen. Psychiatry 58, 655-662.
215. Zobel, A.W., Nickel, T., Kunzel, H.E., Ackl, N., Sonntag, A., Ising, M. and Holsboer, F. (2000) "Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated", J. Psychiatry Res. 34, 171-181.
216. Zohar, J., Drummer,D., Edelstein, E.D., Kaiser, N., Belmaker, R.H. and Nir, I. (1985) "Effect of lysine vasopressin in depressed patients on mood and 24-hour rhythm of growth hormone, cortisol, melatonin and prolactin", Psychoneuromdocrinology 10, 273-279.